SAMSUNG BIOLOGICS CO.,LTD. Logo

SAMSUNG BIOLOGICS CO.,LTD.

A CDMO providing end-to-end development and manufacturing services for the biopharma industry.

207940 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
인천광역시 연수구 송도바이오대로 300, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) providing end-to-end services to the global biopharmaceutical industry. The company offers a comprehensive service suite from late discovery, cell line and process development to large-scale, CGMP-compliant manufacturing of drug substance (DS) and drug product (DP). Its offerings also include analytical testing services and development support for new modalities such as antibody-drug conjugates (ADCs) and mRNA. Leveraging advanced infrastructure and a strong regulatory track record, Samsung Biologics supports its clients, which include many of the world's leading pharmaceutical companies, from clinical development through to commercial supply.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SAMSUNG BIOLOGICS CO.,LTD. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-11 00:00
Registration Form
[기재정정]증권신고서(분할)
Korean 4.7 MB
2025-09-09 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 8.2 KB
2025-09-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-05 00:00
Environmental & Social Information
지속가능경영보고서등관련사항(자율공시)
Korean 16.8 KB
2025-09-02 00:00
Registration Form
[기재정정]증권신고서(분할)
Korean 5.2 MB
2025-09-01 00:00
Related Party Transaction
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 10.2 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-08-26 00:00
Regulatory News Service
단일판매ㆍ공급계약체결(자율공시)
Korean 7.7 KB
2025-08-25 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 37.5 KB
2025-08-22 00:00
M&A Activity
[기재정정]주요사항보고서(회사분할결정)
Korean 56.1 KB
2025-08-22 00:00
Registration Form
증권신고서(분할)
Korean 4.5 MB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 4.5 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.0 MB

Automate Your Workflow. Get a real-time feed of all SAMSUNG BIOLOGICS CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SAMSUNG BIOLOGICS CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden KLAR
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan 9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan 4967
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896

Talk to a Data Expert

Have a question? We'll get back to you promptly.